CAC
TGTX icon

Cowen and Company’s TG Therapeutics TGTX Stock Holding History

Cowen and Company’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-112,000
Closed -$813K – 731
2022
Q3 		$129K Buy
+112,000
New +$735K 0.01% 199
2021
Q4 		– Sell
-4,992
Closed -$166K – 749
2021
Q3 		$166K Buy
+4,992
New +$154K 0.01% 280

Other funds holding TGTX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.77B AUM 307.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JFG
Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Cowen and Company's TGTX Position: Q4 2022 in Review

Cowen and Company sold out of TG Therapeutics (TGTX) in Q4 2022, closing a stake of 112,000 shares — an estimated $813K sold.

Cowen and Company first reported a position in TGTX in Q3 2021 and held it in 2 quarters. The position peaked at $166K in Q3 2021. 198 funds tracked by Wall St. Rank hold TGTX as of Q4 2022.

  • Cowen and Company reported no remaining TG Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Cowen and Company sold 112,000 TG Therapeutics shares in Q4 2022, an estimated $813K.
  • Cowen and Company first reported a position in TG Therapeutics in Q3 2021 and held it in 2 quarters.
  • Cowen and Company's TG Therapeutics position peaked at $166K in Q3 2021.
  • 198 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2022.

Based on Cowen and Company's 13F filing for Q4 2022, filed 9 Feb 2023.